TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
March 2026
Studysummary In this clinical trial, patients with lichen planopilaris treated with the oral TYK2 inhibitor deucravacitinib showed significant improvement in PGA, LPPAI, and Skindex-16 scores over 24 weeks, with transcriptomic analyses indicating decreased inflammatory and immune pathway activity post-treatment.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on medrxiv.org →